Clinical Trials Update: Aug. 23, 2007

-- Here are the latest clinical trials, courtesy of Thomson CenterWatch:

Cancer Pain

This study will evaluate whether an experimental drug known as CG5503 (tapentadol) extended release is safe and effective when used by people who have long-lasting or frequently recurring cancer-related pain. The study drug and study procedures will be provided at no cost. To qualify, you must be at least 18 and have chronic cancer-related pain. Additional criteria may apply.

The research site is in Englewood, N.J.

More information

Please see http://www.centerwatch.com/patient/studies/cat303.html.

-----

Acne

This study will compare the effectiveness of the study drug vs. a placebo to treat acne vulgaris. Study drug and procedures will be provided at no cost. To qualify, you must be at least 12 years old and have moderate-to-severe facial acne. You will not qualify if you are pregnant or breast-feeding, have facial sunburns, or have participated in any drug study within the last 30 days.

The research site is in New York City.

More information

Please see http://www.centerwatch.com/patient/studies/cat1.html.

-----

Pancreatic Cancer

This study will assess the effectiveness and safety of an investigational product vs. capecitabine in people with advanced or metastatic pancreatic cancer who have failed first-line therapy with gemcitabine. To participate, you must be 18 years or older with confirmed pancreatic cancer and have failed first-line gemcitabine therapy. Additional criteria may apply.

The research site is in Santa Maria, Calif.

More information

Please see http://www.centerwatch.com/patient/studies/cat35.html.

-----

Copyright 2007 CenterWatch. All rights reserved.

Posted: August 2007


View comments

Hide
(web2)